New antiepileptic drugs currently in clinical trials: Is there a strategy in their development?

被引：21

作者：

Bialer, M

机构：

[1] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel

[2] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, David R Bloom Ctr, IL-91120 Jerusalem, Israel

来源：

THERAPEUTIC DRUG MONITORING | 2002年 / 24卷 / 01期

关键词：

new antiepileptic drugs; second-generation antiepileptic drugs; pharmacokinetic-based drug design; pharmacodynamic-based drug design;

D O I：

10.1097/00007691-200202000-00015

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

In designing and developing antiepileptic drugs (AEDs), attention should be paid to the desirable pharmacokinetic properties of potential new agents so that molecules are designed to achieve the desired pharmacodynamic and pharmacokinetic profiles. A review of current compounds in development or in clinical trials shows that several promising agents have incorporated pharmacokinetic-based design into their development process. This is particularly true for new AEDs that are second-generation or follow-up compounds of existing AEDs.

引用

页码：85 / 90

页数：6

共 21 条

[1] Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference [J].